July 21, 2026 | US Market Briefing: Chip Stocks Drag Nasdaq Higher as VIX Tumbles Below 18
The Nasdaq closed up 1.29% at 25,837.21 points—its best single-day performance in weeks. The S&P 500 gained 0.89% to 7,509.20, while the Dow rose 0.74% to 52,224.64. All three indices moved up with clear tiering: tech (XLK) surged 2.89%, nearly two percentage points ahead of second-place energy (XLE), which climbed just 0.97%. The VIX dropped from above 18 to 17.05, down 8.58% in a single day.
Chips led the charge. SMCI nailed its earnings: gross margins doubled and backlog hit $60 billion, sending shares soaring and lifting the entire semiconductor sector. MU followed up with a 4.91% gain; NBIS jumped 12.34%. The AI compute story has been running for two years—but as long as order books keep expanding, there’s no reason for capital to exit.
On energy, Middle East tensions continue propping up oil prices. WTI rose 1.97% to $84.87 per barrel; geopolitical risk premiums show no sign of fading soon, so energy stocks are eating well too. Meanwhile, consumer staples (XLP) fell 0.94%, leading the losers as money rotated out of defensive plays and into offensive ones—a clear shift in risk appetite.
On rates, the 10-year U.S. Treasury yield climbed to 4.63%. Polymarket now assigns an 84% probability that interest rates will hold steady at July’s FOMC meeting; rate-cut expectations are receding further. Jamie Dimon dropped a blunt truth right on cue: given current valuations, JPMorgan won’t touch large-cap equities or long-dated Treasuries. If even one of the biggest buyers thinks it’s too expensive, expect little new money to flow into bonds anytime soon.
Per Semafor, Intel and SK Hynix haven’t started talks on their Ohio chip campus deal. But according to Korea’s JoongAng Ilbo citing industry officials, SK Hynix is negotiating an acquisition of the site with plans to produce chips in the U.S. within five years. If it goes through, this marks another step by South Korea’s storage giant toward domestic manufacturing—chip localization is accelerating from slogan to factory floor faster than ever.
Two policy threads stand out: Trump announced a 100% tariff on generic drugs starting two years from now and will head to Michigan next week. The two-year window limits near-term impact, but pharma companies are already factoring supply-chain restructuring costs into their outlooks. Separately, reports say the White House is pushing for $200 billion in R&D funding for researchers—fiscal firepower for tech competition is ramping up.
Today’s market structure tells a story: chip leaders rose on earnings and order books; selling pressure in defensive sectors signals active capital rotation toward offense. When should we start worrying again? Watch two triggers: VIX climbing above 20 for three straight days, or the 10-year yield breaking through 4.75% toward the psychological 5% barrier. Until then, tech-driven upside momentum looks set to continue.